Rexahn featured in Biotechnology Report in the Wall Street Journal



Rexahn CEO, Dr. Chang Ahn, discusses Serdaxin as a potential treatment for Parkinson’s. Read the article in page 2 of the report here.

Share and Enjoy:

  • email
  • Twitter
  • del.icio.us
  • Facebook
  • Google Bookmarks